View Moderna Vaccine Trials Background. The investigational vaccine was developed by the biotechnology company moderna and the national institute of allergy and infectious diseases, part of the national institutes of health. The trial involved 30,000 people in the us with half being given two doses of the vaccine, four weeks apart.

Moderna Inc. (NASDAQ:MRNA) Releases Positive Data For Its ... from www.wallstreetpr.com

Moderna's mrna vaccine reaches its final phase. Moderna says it is a great day and they plan to apply for approval to use the vaccine in the next few weeks. One of the people in the.

Pfizer's trial, which is not part of operation warp speed, has enrolled half the participants in both trials receive the study vaccine and half receive a placebo, and more than 25,000 of moderna's participants have already.

Pfizer and moderna were the first to announce early data on large studies, but 10 other companies are also conducting big phase 3 trials in a global race to produce a vaccine, including efforts in australia. Moderna's vaccine reached phase i human trials on march 16, only 63 days after the company began developing it. Including moderna's vaccine candidate, just four potential vaccines have advanced to phase 3 trials so far. Moderna announced monday that its vaccine can be stable at refrigerator temperatures for a month and frozen for up to six months.